Akcea Theraps Drug Patent Portfolio

Akcea Theraps owns 1 orange book drug protected by 6 US patents Given below is the list of Akcea Theraps's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8697860 Diagnosis and treatment of disease 29 Apr, 2031
Active
US9061044 Modulation of transthyretin expression 29 Apr, 2031
Active
US9399774 Modulation of transthyretin expression 29 Apr, 2031
Active
US8101743 Modulation of transthyretin expression 01 Apr, 2025
Active
US7101993 Oligonucleotides containing 2′-O-modified purines 05 Sep, 2023 Expired
US7015315 Gapped oligonucleotides 21 Mar, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Akcea Theraps.

Activity Date Patent Number
Patent litigations
Patent Term Extension Application under 35 USC 156 Filed 16 Feb, 2024 US8101743
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jan, 2024 US9399774
FDA Final Eligibility Letter 14 Nov, 2023 US8101743
FDA Final Eligibility Letter 14 Nov, 2023 US9061044
Payment of Maintenance Fee, 12th Year, Large Entity 12 Jul, 2023 US8101743
transaction for FDA Determination of Regulatory Review Period 28 Mar, 2023 US9061044
transaction for FDA Determination of Regulatory Review Period 28 Mar, 2023 US9399774
transaction for FDA Determination of Regulatory Review Period 28 Mar, 2023 US8101743
transaction for FDA Determination of Regulatory Review Period 23 Mar, 2023 US9061044
transaction for FDA Determination of Regulatory Review Period 23 Mar, 2023 US8101743
transaction for FDA Determination of Regulatory Review Period 23 Mar, 2023 US9399774
Payment of Maintenance Fee, 8th Year, Large Entity 07 Dec, 2022 US9061044
Payment of Maintenance Fee, 8th Year, Large Entity 29 Sep, 2021 US8697860
Second letter to regulating agency to determine regulatory review period 17 Aug, 2020 US8101743
Second letter to regulating agency to determine regulatory review period 17 Aug, 2020 US9061044


Akcea Theraps's Drug Patent Litigations

Akcea Theraps's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 18, 2000, against patent number US7015315. The petitioner , challenged the validity of this patent, with COOK et al as the respondent. Click below to track the latest information on how companies are challenging Akcea Theraps's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7015315 September, 2004 Decision
(27 Apr, 2005)
COOK et al
US7015315 October, 2000 Decision
(31 Oct, 2002)
COOK et al


Akcea Theraps's Family Patents

Akcea Theraps drugs have patent protection in a total of 24 countries. It has a significant patent presence in the US with 51.8% of its patents being US patents. Click below to unlock the full patent family tree.

Family Patents



Akcea Theraps Drug List

Given below is the complete list of Akcea Theraps's drugs and the patents protecting them.


1. Tegsedi

Tegsedi is protected by 6 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8697860 Diagnosis and treatment of disease 29 Apr, 2031
(6 years from now)
Active
US9061044 Modulation of transthyretin expression 29 Apr, 2031
(6 years from now)
Active
US9399774 Modulation of transthyretin expression 29 Apr, 2031
(6 years from now)
Active
US8101743 Modulation of transthyretin expression 01 Apr, 2025
(5 months from now)
Active
US7101993 Oligonucleotides containing 2′-O-modified purines 05 Sep, 2023
(1 year, 1 month ago)
Expired
US7015315 Gapped oligonucleotides 21 Mar, 2023
(1 year, 6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tegsedi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List